Clinical Trial Update: Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing systemic exposure from different ciclesonide formulations (nasal spray, nasal aerosol, and orally inhaled) in allergic rhinitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Ciclesonide nasal spray (ciclesonide)
• Orally inhaled ciclesonide (ciclesonide)
• ciclesonide HFA nasal aerosol (ciclesonide)

Snippet

Sponsor: Covis Pharma S.à.r.l. | Conditions: Allergic Rhinitis | Phase 4 | Status: COMPLETED | Results posted: 2022-03-02